Cargando…

Early phase trials in soft-tissue sarcomas: clinical benefit of inclusion in early lines of treatment, molecular screening, and histology-driven trials

BACKGROUND: The prognosis of patients with advanced soft-tissue sarcomas (STS) remains dismal, and systemic therapeutic options are limited. Early phase trials are becoming increasingly safe and effective. This study aimed to identify the prognostic factors for progression-free survival (PFS). PATIE...

Descripción completa

Detalles Bibliográficos
Autores principales:	Nassif, E.F., Blay, J.-Y., Massard, C., Dufresne, A., Brahmi, M., Cassier, P., Ray-Coquard, I., Pautier, P., Leary, A., Sunyach, M.-P., Bahleda, R., Levy, A., Le Pechoux, C., Honoré, C., Mir, O., Le Cesne, A.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2022
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9058915/ https://www.ncbi.nlm.nih.gov/pubmed/35255445 http://dx.doi.org/10.1016/j.esmoop.2022.100425

Ejemplares similares

TP53 Mutation as a Prognostic and Predictive Marker in Sarcoma: Pooled Analysis of MOSCATO and ProfiLER Precision Medicine Trials
por: Nassif, Elise F., et al.
Publicado: (2021)

Identification of patients at risk for early death after conventional chemotherapy in solid tumours and lymphomas
por: Ray-Coquard, I, et al.
Publicado: (2001)

Baseline and early lymphopenia predict for the risk of febrile neutropenia after chemotherapy
por: Ray-Coquard, I, et al.
Publicado: (2003)

Patterns of care and outcomes of patients with METAstatic soft tissue SARComa in a real-life setting: the METASARC observational study
por: Savina, Marion, et al.
Publicado: (2017)

Outcomes of patients with metastatic gastrointestinal stromal tumors (GIST) treated with multi-kinase inhibitors other than imatinib as first-line treatment
por: Boilève, Alice, et al.
Publicado: (2020)

Neoadjuvant imatinib in patients with locally advanced non metastatic GIST in the prospective BFR14 trial
por: Blesius, Aurore, et al.
Publicado: (2011)

KIT exon 10 variant (c.1621 A > C) single nucleotide polymorphism as predictor of GIST patient outcome
por: Brahmi, Mehdi, et al.
Publicado: (2015)

Recombinant erythropoietin for the anaemia of patients with advanced Gastrointestinal Stromal Tumours (GIST) receiving imatinib: an active agent only in non progressive patients
por: Duffaud, Florence, et al.
Publicado: (2012)

Long term term follow-up of tyrosine kinase inhibitors treatments in inoperable or relapsing diffuse type tenosynovial giant cell tumors (dTGCT)
por: Brahmi, Mehdi, et al.
Publicado: (2020)

Expression and prognostic significance of PDGF ligands and receptors across soft tissue sarcomas
por: Brahmi, M., et al.
Publicado: (2021)

Very long‐term survivors among patients with metastatic soft tissue sarcoma
por: Carbonnaux, Mélodie, et al.
Publicado: (2019)

French Sarcoma Group proposals for management of sarcoma patients during the COVID-19 outbreak
por: Penel, N., et al.
Publicado: (2020)

Specific immune landscapes and immune checkpoint expressions in histotypes and molecular subtypes of sarcoma
por: Dufresne, A., et al.
Publicado: (2020)

Abdominal desmoplastic small round cell tumor without extraperitoneal metastases: Is there a benefit for HIPEC after macroscopically complete cytoreductive surgery?
por: Honoré, C., et al.
Publicado: (2017)

Novel Therapeutic Options for Solitary Fibrous Tumor: Antiangiogenic Therapy and Beyond
por: de Bernardi, Axel, et al.
Publicado: (2022)

Identification of biological factors predictive of response to imatinib mesylate in aggressive fibromatosis
por: Dufresne, A, et al.
Publicado: (2010)

Natural history and treatment efficacy in an ambispective case series of NTRK-rearranged mesenchymal tumors
por: Dufresne, A., et al.
Publicado: (2023)

Expanding the molecular spectrum of tenosynovial giant cell tumors
por: Gauduchon, Thibault, et al.
Publicado: (2022)

Phase I clinical trial combining imatinib mesylate and IL-2 in refractory cancer patients: IL-2 interferes with the pharmacokinetics of imatinib mesylate
por: Pautier, Patricia, et al.
Publicado: (2013)

Therapeutic relevance of molecular screening program in patients with metastatic sarcoma: Analysis from the ProfiLER 01 trial
por: Arnaud-Coffin, Patrick, et al.
Publicado: (2020)

Molecular Classification of Endometrial Stromal Sarcomas Using RNA Sequencing Defines Nosological and Prognostic Subgroups with Different Natural History
por: Brahmi, Mehdi, et al.
Publicado: (2020)

Pregnancy in Women with Metastatic Sarcomas
por: Yazigi, Alexandre, et al.
Publicado: (2020)

Efficacy and Safety of Adjuvant Radiotherapy in Re-excised Soft-tissue Sarcoma After Unplanned Resection
por: Allignet, Benoît, et al.
Publicado: (2023)

Trabectedin and its potential in the treatment of soft tissue sarcoma
por: Cassier, Philippe A, et al.
Publicado: (2008)

Antiangiogenic effects in patients with progressive desmoplastic small round cell tumor: data from the French national registry dedicated to the use of off-labeled targeted therapy in sarcoma (OUTC’s)
por: Bétrian, Sarah, et al.
Publicado: (2017)

Tocilizumab for the treatment of paraneoplastic inflammatory syndrome associated with angiomatoid fibrous histiocytoma
por: Eberst, Lauriane, et al.
Publicado: (2020)

Expression and role of TYRO3 and AXL as potential therapeutical targets in leiomyosarcoma
por: Dantas-Barbosa, Carmela, et al.
Publicado: (2017)

Access to early-phase clinical trials in older patients with cancer in France: the EGALICAN-2 study
por: Baldini, C., et al.
Publicado: (2022)

Prognostic and predictive factors for angiosarcoma patients receiving paclitaxel once weekly plus or minus bevacizumab: an ancillary study derived from a randomized clinical trial
por: Lebellec, Loïc, et al.
Publicado: (2018)

Clear Cell Sarcoma (Malignant Melanoma) of Soft Parts: A Clinicopathologic Study of 52 Cases
por: Hocar, O., et al.
Publicado: (2012)

Pazopanib for the treatment of soft-tissue sarcoma
por: Heudel, Pierre, et al.
Publicado: (2012)

Single‐agent gemcitabine in patients with advanced, pre‐treated angiosarcoma: A multicenter, retrospective study
por: Watson, Sarah, et al.
Publicado: (2022)

A phase II trial of panobinostat in patients with advanced pretreated soft tissue sarcoma. A study from the French Sarcoma Group
por: Cassier, P A, et al.
Publicado: (2013)

The off-label use of targeted therapies in sarcomas: the OUTC’S program
por: Eberst, Lauriane, et al.
Publicado: (2014)

Masitinib in advanced gastrointestinal stromal tumor (GIST) after failure of imatinib: A randomized controlled open-label trial
por: Adenis, A., et al.
Publicado: (2014)

Surgery in reference centers improves survival of sarcoma patients: a nationwide study
por: Blay, J -Y, et al.
Publicado: (2019)

Surgery in reference centers improves survival of sarcoma patients: a nationwide study
por: Blay, J -Y, et al.
Publicado: (2019)

Inequality factors in access to early-phase clinical trials in oncology in France: results of the EGALICAN-2 study
por: Charton, E., et al.
Publicado: (2023)

1617P Sustained cancer clinical trial activity during the COVID-19 pandemic
por: Bayle, A., et al.
Publicado: (2021)

Reasons for acceptance and refusal of early palliative care in patients included in early-phase clinical trials in a regional comprehensive cancer centre in France: protocol for a qualitative study
por: Chvetzoff, Gisele, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_qul8k2hsb2aehpmnpjniis8abg